Drug Profile
APL 509
Alternative Names: 10B10 antibody; Anti CTLA-4 antibody - Apollomics; APL-509; CBT-509Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Crown Bioscience
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer